MedPath

BMS-986020

Generic Name
BMS-986020
Drug Type
Small Molecule
Chemical Formula
C29H26N2O5
CAS Number
1257213-50-5
Unique Ingredient Identifier
38CTP01B4L
Background

BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo
Drug: Interferon alpha-2a recombinant
First Posted Date
2016-05-05
Last Posted Date
2017-08-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
357
Registration Number
NCT02763969
Locations
πŸ‡¦πŸ‡Ί

Local Institution, Melbourne, Australia

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Phase 2
Withdrawn
Conditions
Scleroderma
Interventions
Other: Placebo
First Posted Date
2015-10-28
Last Posted Date
2016-07-22
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT02588625
Locations
πŸ‡¬πŸ‡§

Local Institution, London, Greater London, United Kingdom

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Phase 1
Completed
Conditions
Drug-drug Interaction Study
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-11-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT02227173
Locations
πŸ‡ΊπŸ‡Έ

Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States

Drug Interaction Study With Rosuvastatin

Phase 1
Completed
Conditions
Immunosuppression For Disease
Interventions
First Posted Date
2014-04-01
Last Posted Date
2014-06-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
26
Registration Number
NCT02101125
Locations
πŸ‡ΊπŸ‡Έ

Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Phase 1
Completed
Conditions
Immunosuppression For Disease
Interventions
First Posted Date
2014-02-20
Last Posted Date
2014-06-02
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
6
Registration Number
NCT02068053

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Phase 1
Completed
Conditions
Immunology
Interventions
First Posted Date
2013-12-23
Last Posted Date
2015-07-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT02017730
Locations
πŸ‡ΊπŸ‡Έ

Yale Pet Center, New Haven, Connecticut, United States

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Phase 2
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo matching with BMS-986020
First Posted Date
2013-01-11
Last Posted Date
2020-08-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
325
Registration Number
NCT01766817
Locations
πŸ‡ΊπŸ‡Έ

Weill Cornell Medical College, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Cleveland Clinic Florida- Weston Hospital, Weston, Florida, United States

πŸ‡΅πŸ‡ͺ

Local Institution, Lima, Peru

and more 50 locations
Β© Copyright 2025. All Rights Reserved by MedPath